Inhibikase Therapeutics, Inc. (IKT)
NASDAQ: IKT · Real-Time Price · USD
2.400
-0.040 (-1.64%)
Aug 5, 2026, 4:00 PM EDT - Market closed
Inhibikase Therapeutics Employees
Inhibikase Therapeutics had 35 employees as of December 31, 2025. The number of employees increased by 19 or 118.75% compared to the previous year.
Employees
35
Change (1Y)
19
Growth (1Y)
118.75%
Revenue / Employee
n/a
Profits / Employee
-$1,456,037
Market Cap
469.01M
Employees Chart
| Date | Employees | Change (1Y) | Growth (1Y) | Full-Time | Part-Time |
|---|---|---|---|---|---|
| Dec 31, 2025 | 35 | 19 | 118.75% | 35 | 0 |
| Dec 31, 2024 | 16 | 7 | 77.78% | 15 | 1 |
| Dec 31, 2023 | 9 | 2 | 28.57% | 8 | 1 |
| Dec 31, 2022 | 7 | 0 | - | 6 | 1 |
| Dec 31, 2021 | 7 | 4 | 133.33% | 6 | 1 |
| Dec 31, 2020 | Upgrade Pro | Upgrade Pro | Upgrade Pro | Upgrade Pro | - |
| Sep 30, 2020 | Upgrade Pro | Upgrade Pro | Upgrade Pro | Upgrade Pro | - |
| Jun 30, 2020 | Upgrade Pro | Upgrade Pro | Upgrade Pro | Upgrade Pro | - |
| Mar 31, 2020 | Upgrade Pro | Upgrade Pro | Upgrade Pro | Upgrade Pro | - |
Related Stocks
| Company Name | Employees |
|---|---|
| ProKidney | 231 |
| Cabaletta Bio | 158 |
| Kyverna Therapeutics | 129 |
| Ocugen | 116 |
| Prelude Therapeutics | 79 |
| Prothena Corporation | 67 |
| Eupraxia Pharmaceuticals | 49 |
| Ovid Therapeutics | 23 |
IKT News
- 13 days ago - Inhibikase Therapeutics IKT-001 gets Orphan Drug Designation from FDA - TheFly
- 13 days ago - Inhibikase Therapeutics Announces FDA Orphan Drug Designation Granted to IKT-001 for the Treatment of PAH - GlobeNewsWire
- 20 days ago - Inhibikase Therapeutics’ treatment of PAH granted FDA orphan designation - TheFly
- 22 days ago - Inhibikase Therapeutics Announces Sale of $50 Million of Shares Through its At-the-Market (ATM) Facility - GlobeNewsWire
- 4 weeks ago - Inhibikase Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - GlobeNewsWire
- 2 months ago - Inhibikase Therapeutics initiated with an Outperform at Oppenheimer - TheFly
- 3 months ago - Inhibikase Therapeutics Announces First Quarter 2026 Financial Results and Highlights Recent Activity - GlobeNewsWire
- 3 months ago - Inhibikase Therapeutics Earnings release: Q1 2026 - Filings